

CIRM Funded Clinical Trials

AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110

| | |
|-----------------------------|-----------------------------|
| Disease Area: | Blood Cancer |
| Investigator: | Paul Finnegan |
| Institution: | Angiocrine Bioscience, Inc. |
| CIRM Grant: | CLIN2-10386 |
| Award Value: | \$5,000,000 |
| Trial Sponsor: | Angiocrine Bioscience, Inc. |
| Trial Stage: | Phase 1 |
| Trial Status: | Launching |
| Targeted Enrollment: | N/A |



Paul Finnegan

Details:

Angiocrine is developing a cell therapy aimed to improve the availability and engraftment of blood stem cell transplants for cancer patients who have had their cancerous bone marrow removed by chemotherapy. The cell therapy is made of blood stem cells and endothelial cells, which line blood vessels and are thought to improve the engraftment of the stem cell transplant into the bone marrow. The hope is that this treatment will provide a safer, more tolerable and effective stem cell transplantation that will rebuild the patient's immune system cancer-free.

Design:

First-in-human, Phase 1b open-label, multi-center trial.

Goal:

Safety.

Updates:

Launching.

Source URL: <https://www.cirm.ca.gov/clinical-trial/ab-110-001-phase-1b-trial-and-related-activities-support-clinical-development-ab-110>